公开(公告)号：EP0475206A3

公开(公告)日：1992-08-05

申请号：EP91114542.3

申请日：1991-08-29

Applicant: ABBOTT LABORATORIES

Inventor： Winn, Martin ,  De, Biswanath ,  Zydowsky, Thomas M. ,  Kerkman, Daniel J. ,  De Bernardis, John F. ,  Rosenberg, Saul H. ,  Shiosaki, Kazumi ,  Basha, Fatima Z. ,  Tasker, Andrew S. ,  Von Geldern, Thomas W. ,  Kester, Jeffrey A. ,  Holleman, William H.

IPC: C07D403/12 ,  A61K31/44 ,  C07D401/12 ,  C07D239/42 ,  C07D257/04 ,  C07D405/14 ,  A61K31/495

CPC classification number: C07D239/42 ,  C07D257/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14

Abstract: Novel pyrimidine, pyridine, pyridazine, pyrazine and triazine compounds are provided of the formula (I).
The compounds of the invention are useful for treating hypertension, edema, renal failure, congestive heart failure, psoriasis and glaucoma, and in the prevention and treatment of atherosclerosis or to treat gastrointestinal disorders associated with enhanced contractility and/or motility of intestinal smooth muscle or to treat contractile disorders of the uterus.

公开(公告)号：EP0230532A1

公开(公告)日：1987-08-05

申请号：EP86115057.1

申请日：1986-10-30

Applicant: ABBOTT LABORATORIES

Inventor： Winn, Martin ,  De Bernardis, John Francis

IPC: C07D233/24 ,  A61K31/415

CPC classification number: C07D233/24

Abstract: Disclosed herein are alpha adrenergic and nasal decongestant compounds of the formula
wherein R₁ and R₂, each being the same or different, are halogens, and the pharmaceutically acceptable salts thereof.

公开(公告)号：EP1609790A3

公开(公告)日：2006-01-04

申请号：EP05106190.1

申请日：1997-02-12

Applicant: ABBOTT LABORATORIES

Inventor： Winn, Martin ,  Henry, Kenneth J. Jr. ,  Liu, Gang ,  Wittenberger, Steven J. ,  King, Steven A. ,  Boyd, Steven A. ,  Hutchins, Charles W. ,  Jae, Hwan-Soo ,  Tasker, Andrew S. ,  Von Geldern, Thomas W. ,  Kester, Jeffrey A. ,  Sorensen, Bryan K. ,  Szczepankiewicz, Bruce G.

IPC: C07D405/04 ,  C07D405/12 ,  A61K31/40 ,  A61K31/41 ,  A61K31/435

CPC classification number: C07D401/04 ,  C07D207/16 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  Y02P20/55

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

公开(公告)号：EP1481968A3

公开(公告)日：2005-01-19

申请号：EP04020808.4

申请日：2000-04-03

Applicant: Abbott Laboratories

Inventor： Link, James ,  Liu, Gang ,  Pei, Zhonghua ,  von Geldern, Thomas W. ,  Winn, Martin ,  Xin, Zhili ,  Wang, Sheldon ,  Boyd, Steven A. ,  Zhu, Gui-Dong ,  Freeman, Jennifer C. ,  Gunawardana, Indrani W. ,  Staeger, Michael A. ,  Jae, Hwan-Soo ,  Lynch, John K.

IPC: C07C323/62 ,  C07D233/61 ,  C07D207/26 ,  C07D295/18 ,  C07D213/74 ,  C07D211/22 ,  C07D207/14 ,  C07D211/46 ,  C07D211/62 ,  C07D211/60 ,  C07D401/04 ,  C07D217/02 ,  C07D307/68 ,  C07D295/26 ,  C07D317/66 ,  C07D209/08 ,  C07D295/205 ,  C07D401/12 ,  A61K31/165 ,  A61K31/33 ,  A61P29/00

CPC classification number: C07D207/27 ,  C07C323/62 ,  C07C2601/02 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D207/16 ,  C07D209/08 ,  C07D211/20 ,  C07D211/22 ,  C07D211/46 ,  C07D211/60 ,  C07D211/62 ,  C07D213/40 ,  C07D213/74 ,  C07D213/81 ,  C07D217/02 ,  C07D217/06 ,  C07D231/12 ,  C07D233/56 ,  C07D241/04 ,  C07D249/08 ,  C07D295/185 ,  C07D295/26 ,  C07D307/68 ,  C07D317/66 ,  C07D401/04 ,  C07D401/12

Abstract: The present invention relates to cinnamide compounds of formula (I), in which at least one of R 1 to R 5 is a "cis-cinnamide" (a) or a "trans-cinnamide" (b) and the other variables are as defined in the claims, that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Abstract translation: 本发明涉及式（I）的肉桂酰胺化合物，其中R 1至R 5中的至少一个为“顺式 - 酰胺”（a）或“反式肉桂酰胺”（b），其它变量如 可用于治疗炎症和免疫疾病的权利要求，含有这些化合物的药物组合物和抑制哺乳动物炎症或抑制免疫应答的方法。

公开(公告)号：EP0475206A2

公开(公告)日：1992-03-18

申请号：EP91114542.3

申请日：1991-08-29

Applicant: ABBOTT LABORATORIES

Inventor： Winn, Martin ,  De, Biswanath ,  Zydowsky, Thomas M. ,  Kerkman, Daniel J. ,  De Bernardis, John F. ,  Rosenberg, Saul H. ,  Shiosaki, Kazumi ,  Basha, Fatima Z. ,  Tasker, Andrew S. ,  Von Geldern, Thomas W. ,  Kester, Jeffrey A. ,  Holleman, William H.

IPC: C07D403/12 ,  A61K31/44 ,  C07D401/12 ,  C07D239/42 ,  C07D257/04 ,  C07D405/14 ,  A61K31/495

CPC classification number: C07D239/42 ,  C07D257/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14

Abstract: Novel pyrimidine, pyridine, pyridazine, pyrazine and triazine compounds are provided of the formula (I).

The compounds of the invention are useful for treating hypertension, edema, renal failure, congestive heart failure, psoriasis and glaucoma, and in the prevention and treatment of atherosclerosis or to treat gastrointestinal disorders associated with enhanced contractility and/or motility of intestinal smooth muscle or to treat contractile disorders of the uterus.

Abstract translation: 由式（I）提供新的嘧啶，吡啶，哒嗪，吡嗪和三嗪化合物。 本发明的化合物可用于治疗高血压，水肿，肾衰竭，充血性心力衰竭，牛皮癣和青光眼，以及预防和治疗动脉粥样硬化或治疗与增强的肠收缩力和/或运动性相关的胃肠道疾病 平滑肌或治疗子宫收缩性疾病。

公开(公告)号：EP1609790A2

公开(公告)日：2005-12-28

申请号：EP05106190.1

申请日：1997-02-12

Applicant: ABBOTT LABORATORIES

Inventor： Winn, Martin ,  Henry, Kenneth J. Jr. ,  Liu, Gang ,  Wittenberger, Steven J. ,  King, Steven A. ,  Boyd, Steven A. ,  Hutchins, Charles W. ,  Jae, Hwan-Soo ,  Tasker, Andrew S. ,  Von Geldern, Thomas W. ,  Kester, Jeffrey A. ,  Sorensen, Bryan K. ,  Szczepankiewicz, Bruce G.

IPC: C07D405/04 ,  C07D405/12 ,  A61K31/40 ,  A61K31/41 ,  A61K31/435

CPC classification number: C07D401/04 ,  C07D207/16 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  Y02P20/55

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Abstract translation: 公开了式（I）化合物或其药学上可接受的盐，以及其制备方法和中间体，以及拮抗内皮素的方法。

公开(公告)号：EP1186603A2

公开(公告)日：2002-03-13

申请号：EP01125462.0

申请日：1995-08-04

Applicant: Abbott Laboratories

Inventor： Winn, Martin ,  Boyd Steven A. ,  Hutchins, Charles W. ,  Jae, Hwan-Soo ,  Tasker, Andrew S. ,  Vongeldern, Thomas W. ,  Kester, Jeffrey A. ,  Sorensen, Bryan K.

IPC: C07D405/04 ,  C07D207/16 ,  C07D405/14 ,  C07D403/04 ,  C07D401/04 ,  A61K31/4025

CPC classification number: C07D401/04 ,  C07D207/16 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07F9/5722 ,  C07F9/592

Abstract: Processes for preparing endothelin antagonists of formula (I) and pharmaceutically acceptable salts thereof and processes for preparing intermediates thereof.

Abstract translation: 用于制备式（I）的内皮素拮抗剂及其药学上可接受的盐的方法及其制备中间体的方法。

公开(公告)号：EP0170093B1

公开(公告)日：1990-03-07

申请号：EP85108276.8

申请日：1985-07-05

Applicant: ABBOTT LABORATORIES

Inventor： DeBernardis, John F. ,  Winn, Martin

IPC: C07D209/94 ,  A61K31/40

CPC classification number: C07C62/34 ,  C07D209/94

公开(公告)号：EP0170093A1

公开(公告)日：1986-02-05

申请号：EP85108276.8

申请日：1985-07-05

Applicant: ABBOTT LABORATORIES

Inventor： DeBernardis, John F. ,  Winn, Martin

IPC: C07D209/94 ,  A61K31/40

CPC classification number: C07C62/34 ,  C07D209/94

Abstract: Disclosed herein are 1,2,3,3a,8,8a-hexahydroindeno[1,2-c]pyrroles represented by the formula

wherein R, is hydrogen, loweralkyl, arylalkyl, loweracyl or benzoalkylenedioxy; R 2 and R 3 may be the same or different and are loweralkoxy, halo, thiomethyl, loweracyl, NR 2 R 3 , NHSO 2 R 2 or arylalkoxy or R 2 and R 3 taken together may form a methylenedioxy or ethylenedioxy bridge.

Abstract translation: 本文公开了由下式表示的1,2,3,3a，8,8a-六氢茚并[1,2-c]吡咯：其中R1是氢，低级烷基，芳基烷基，低级别色烯基或苯并亚烷基二氧基; R 2和R 3可以相同或不同，为低级烷氧基，卤代，硫代甲基，低级二芳基，NR 2 R 3，NHSO 2 R 2或芳基烷氧基，或者R 2和R 3一起形成亚甲二氧基或亚乙二氧基桥。

公开(公告)号：EP2269977A3

公开(公告)日：2011-04-27

申请号：EP10178769.5

申请日：2006-01-05

Applicant: Abbott Laboratories

Inventor： Patel, Jyoti, R. ,  Shuai, Qi ,  Link, James, T. ,  Rohde, Jeffrey, J. ,  Dinges, Jurgen ,  Sorensen, Bryan, K. ,  Winn, Martin ,  Yong, Hong ,  Yeh, Vince, S.

IPC: C07C235/14 ,  C07C317/16 ,  C07C323/41 ,  C07D257/04 ,  C07D233/54 ,  C07D261/08 ,  C07D213/64 ,  C07D207/48 ,  A61K31/4402 ,  A61P3/10

CPC classification number: C07C233/23 ,  C07C235/14 ,  C07C237/24 ,  C07C255/31 ,  C07C255/47 ,  C07C259/16 ,  C07C311/08 ,  C07C311/29 ,  C07C311/46 ,  C07C311/51 ,  C07C317/22 ,  C07C317/30 ,  C07C317/44 ,  C07C323/41 ,  C07C323/60 ,  C07C2601/04 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2602/08 ,  C07C2602/10 ,  C07C2603/74 ,  C07D207/48 ,  C07D213/64 ,  C07D233/64 ,  C07D257/04 ,  C07D261/08

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract translation: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。